Related Experiment Video
Updated: Jun 27, 2026

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
Culprit and victim -- DNA topoisomerase II
Udo Kellner1, Maxwell Sehested, Peter B Jensen
1Department of Pathology, University of Magdeburg, Magdeburg, Germany. udo.kellner@medizin.uni-magdeburg.de
Abstract:
The phylogenetic antiquity of DNA topoisomerases indicates their vital function. Structure and maintenance of genomic DNA depend on the activity of these enzymes, and without them DNA replication and cell division are impossible. Topoisomerase II alpha has therefore become the main target of many antitumour therapy regimens, even though the exact mechanism of cell killing remains elusive. The success of this approach is limited by the development of spontaneous resistance, and drug-induced DNA damage can increase malignancy. Nevertheless, the combined use of topoisomerase-inhibiting drugs with different mechanisms of action promises to improve particular treatment designs. The degree of topoisomerase II expression in tumours may predict the clinical course and responsiveness to therapy.
Insights
DNA topoisomerases are essential for DNA replication and cell division. Targeting Topoisomerase II alpha in cancer therapy shows promise, but resistance is a challenge, necessitating combined treatment strategies.
Area of Science:
- Genetics and Molecular Biology
- Cancer Therapeutics
Background:
- DNA topoisomerases are phylogenetically ancient enzymes crucial for genomic DNA structure, replication, and cell division.
- Topoisomerase II alpha is a key target in antitumour therapy, though its precise cell-killing mechanisms and associated resistance are not fully understood.
Purpose of the Study:
- To explore the role of Topoisomerase II alpha in cancer therapy.
- To investigate strategies for overcoming resistance to Topoisomerase II inhibitors.
- To assess the predictive value of Topoisomerase II expression in tumour response to therapy.
Main Methods:
- Review of existing literature on DNA topoisomerases and cancer therapy.
- Analysis of mechanisms of action for Topoisomerase II inhibitors.
- Examination of resistance development and potential combination therapies.
Main Results:
- Topoisomerase II alpha is vital for cell proliferation, making it a validated cancer target.
- Resistance to Topoisomerase II inhibitors can develop, limiting treatment efficacy.
- Combining different Topoisomerase II inhibiting drugs may enhance therapeutic outcomes.
- Tumour Topoisomerase II expression levels may correlate with clinical prognosis and treatment response.
Conclusions:
- Topoisomerase II alpha remains a significant target for cancer treatment.
- Developing strategies to circumvent resistance, such as combination therapies, is critical for improving treatment efficacy.
- Further research into Topoisomerase II expression as a predictive biomarker is warranted.
Related Concept Videos
DNA Helicases
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Homologous Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Homologous Recombination

